Pharma
sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Most Viewed Abstracts



Your Article Summary

See Latest Articles
(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Takeda Receives FDA Complete Response Letter for Alogliptin, An Investigational Treatment for Type 2 Diabetes
Takeda Pharmaceuticals North America, 07/02/09

Takeda Pharmaceutical Company Limited announced that Takeda Global Research and Development Center, Inc., a wholly owned United States subsidiary received on June 26 a complete response letter from the U.S. Food and Drug Administration regarding the Company's New Drug Application for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.


Today in Regulatory Issues...keeping you current

Avodart (dutasteride) Regulatory Update
GlaxoSmithKline, 10/02/09

Retigabine Regulatory Update
GlaxoSmithKline, 11/03/09

Beware of Tight 5010 Deadline
HealthDataManagement, 10/16/09

See All of Regulatory Issues

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address